SPPI Class Action: Learn About the Spectrum Pharmaceuticals Lawsuit | Levi & Korsinsky, LLP
Levi & Korsinsky, LLP announces that an SPPI class action lawsuit has been filed on behalf of investors who purchased Spectrum Pharmaceuticals, Inc. (SPPI) securities between December 27, 2018, and August 5, 2021 For more on the SPPI Lawsuit please contact us today.
According to the Spectrum Pharmaceuticals lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the ROLONTIS, an investigational granulocyte-colony stimulating factor analogue, manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application (“BLA”) in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA’s approval prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Spectrum Pharmaceuticals you have until November 1, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171